Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...
In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy ...
New findings show that it is feasible to determine epidermal growth-factor receptor (EGFR) mutations from the blood samples of patients with advanced non-small cell lung cancer (NSCLC) and correlate ...
Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...
CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
SAN FRANCISCO and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Along with the premarket approval of Siemens’ 3D breast-imaging technology, the FDA approved seven oncology and hematology drugs in September. Selpercatinib for patients aged 2 years and older with ...
LOUISVILLE, Ky., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Onco360 ®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE ™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback